绥美凯有耐药性吗？

It is a compound medicine. Each tablet contains 50 mg of dolutegravir sodium, 600 mg of abacavir sulfate, and 300 mg of lamivudine. It is suitable for treating HIV adults and patients over 12 years old.

The three active ingredients contained in Dolutegra Abalamid Tablets play their respective roles. Dolutegravir: Can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). Abacavir: Abacavir is a carbocyclic synthetic nucleoside analog. Abacavir is converted into the active metabolite carbavir triphosphate (CBV-TP) under the action of intracellular enzymes, which is a deoxyguanosine-5'-triphosphate (dGTP) analog. CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and inserting into viral DNA. Lamivudine: Lamivudine is a synthetic nucleoside analogue. Lamivudine is phosphorylated in cells to generate the active 5-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The main mode of action of 3T-CTP is to terminate DNA chain synthesis by inserting nucleotide analogs, thereby inhibiting RT activity.

Does Suimeikai have drug resistance?

Targeted drugs all have one thing in common: after taking them for a period of time, patients will develop drug resistance, and Suimeikai is no exception. The resistance time a patient develops after taking Suimeikai depends on the patient himself. There is no clear standard for the resistance of the human body. If the patient's physical condition is very good, the resistance time will also increase.

Notes: 1. Transmission of HIV. Although viral suppression with antiretroviral therapy has been shown to significantly reduce the risk of sexual transmission, residual risks cannot be excluded. Precautions should be taken to prevent transmission in accordance with national guidance. 2. Immune reconstitution inflammatory syndrome. In severely immunodeficient HIV-infected patients when initiating combination antiretroviral therapy (CART), an inflammatory response to asymptomatic or residual opportunistic pathogens may occur, leading to severe clinical illness or symptom exacerbation. Such reactions are usually observed in the weeks or months before starting CART therapy. Relevant examples include cytomegalovirus retinitis, systemic and/or focal mycobacterial infections, and Pneumocystis jiroveci pneumonia. Symptoms of inflammation should be evaluated and treated if necessary. Autoimmune disorders (e.g., Graves' disease) have also been reported during immune reconstitution; however, the reported timing of onset is inconsistent and these events may occur many months after initiation of therapy. In patients with co-infection with hepatitis B or hepatitis C virus, elevated liver chemistries consistent with immune reconstitution inflammatory syndrome have been observed upon initiation of dolutegravir therapy. In patients with hepatitis B and/or hepatitis C virus infection, monitoring of liver chemistry test values ​​is recommended.